Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence

Tsonis, Orestis; Gkrozou, Fani; Vlachos, Konstantinos; Paschopoulos, Minas; Mitsis, Michail; Zakynthinakis-Kyriakou, Nikolaos; Boussios, Stergios; Pappas-Gogos, George

doi:10.21037/atm-20-1620

Cited by 14 publications

(16 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many clinical practices, complete tumor resection is difficult and debulking surgery is usually used to relief the patient’s symptoms for some advanced tumors such as ovarian carcinoma, neoplasms of central nervous system and lymphoma [ 17 ]. In order to prolong the patients’ lifetimes, efforts have been devoted to explore new intraoperative adjuvant techniques to impede the residual tumour growth, such as intraoperative radiotherapy [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor

Zhang

Guo

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Incomplete tumor resection is the direct cause of the tumor recurrence and metastasis after surgery. Intraoperative accurate detection and elimination of microscopic residual cancer improve surgery outcomes. In this study, a powerful D1–π–A–D2–R type phototheranostic based on aggregation-induced emission (AIE)-active the second near-infrared window (NIR-II) fluorophore is designed and constructed. The prepared theranostic agent, A1 nanoparticles (NPs), simultaneously shows high absolute quantum yield (1.23%), excellent photothermal conversion efficiency (55.3%), high molar absorption coefficient and moderate singlet oxygen generation performance. In vivo experiments indicate that NIR-II fluorescence imaging of A1 NPs precisely detect microscopic residual tumor (2 mm in diameter) in the tumor bed and metastatic lymph nodes. More notably, a novel integrated strategy that achieves complete tumor eradication (no local recurrence and metastasis after surgery) is proposed. In summary, A1 NPs possess superior imaging and treatment performance, and can detect and eliminate residual tumor lesions intraoperatively. This work provides a promising technique for future clinical applications achieving improved surgical outcomes. Graphic Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor

Zhang

Guo

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…HGSOC has the tropism of omental fat and can be used as an energy source. The inability to detect the disease in early diagnosis is one of the main factors for the higher mortality of HGSOC patients [ 3 ]. Studies have shown that only about 13% of serous ovarian cancer cases are diagnosed in stage I or II [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Linc00261 Inhibited High-Grade Serous Ovarian Cancer Progression through miR-552-ATG10-EMT Axis

Wang

Chen

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

In recent years, long non-coding RNAs (lncRNAs) play an important role in a multitude of pathways across species; however, their functions are still unknown. In this study, we demonstrate that Linc00261 is downregulation in high-grade serous ovarian cancer (HGSOC) and can inhibit cell proliferation and migration of high-grade serous ovarian cancer cells. We further validate the targeting interactions among Linc00261, miR-552, and ATG10. Interestingly, they all play important roles for regulating epithelial-mesenchymal transition (EMT) progression. Collectively, these findings suggest that Linc00261, a mediator of EMT progression, can target oncogenic miR-552, elevating ATG10 expression, to prevent high-grade serous ovarian cancer tumorigenesis and may serve as a potential novel therapeutic target.

show abstract

“…[16] In many clinical practices, complete tumor resection is difficult and debulking surgery is usually used to relief the patient's symptoms for some advanced tumors such as ovarian carcinoma, neoplasms of central nervous system and lymphoma. [17] In order to prolong the patients' lifetimes, efforts have been devoted to explore new intraoperative adjuvant techniques to impede the residual tumour growth, such as intraoperative radiotherapy. [18] However, intraoperative radiotherapy can induce ionizing radiation damage.…”

Section: Introductionmentioning

confidence: 99%

Novel Multifunctional NIR-II Aggregation-Induced Emission Nanoparticles Assisted Intraoperative Identification and Elimination of Residual Tumor

Zhang

Guo

et al. 2022

Preprint

View full text Add to dashboard Cite

Incomplete tumor resection is the direct cause of the tumor recurrence and metastasis after surgery. Intraoperative accurate detection and elimination of microscopic residual cancer improve surgery outcomes. In this study, a powerful D1-π-A-D2-R type phototheranostic based on aggregation-induced emission (AIE)-active the second near-infrared window (NIR-II) fluorophore is designed and constructed. The prepared theranostic agent, A1 nanoparticles (NPs), simultaneously shows high absolute quantum yield (1.23%), excellent photothermal conversion efficiency (55.3%), high molar absorption coefficient and moderate singlet oxygen generation performance. In vivo experiments indicate that NIR-II fluorescence imaging of A1 NPs precisely detect microscopic residual tumor (2 mm in diameter) in the tumor bed and metastatic lymph nodes. More notably, a novel integrated strategy that achieves complete tumor eradication (no local recurrence and metastasis after surgery) is proposed. In summary, A1 NPs possess superior imaging and treatment performance, and can detect and eliminate residual tumor lesions intraoperatively. This work provides a promising technique for future clinical applications achieving improved surgical outcomes.

show abstract

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence

Cited by 14 publications

References 78 publications

Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor

Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor

Linc00261 Inhibited High-Grade Serous Ovarian Cancer Progression through miR-552-ATG10-EMT Axis

Novel Multifunctional NIR-II Aggregation-Induced Emission Nanoparticles Assisted Intraoperative Identification and Elimination of Residual Tumor

Contact Info

Product

Resources

About